I believe we did have closer to 10% for IR under Lannett so I expect we’ll get there again soon enough. I disagree with the Vyvanse market size with wave of generic competitors coming online. Maintaining $5B market is completely unrealistic.
Elite has done incredibly well penetrating IR market. ER on the other hand has barely scratched the surface with basically equivalent time in the market. Even if we do 1.5-2x this year vs under Lannett (CEO’s expectations) it’s still a sliver of the ER market held up by the DEA API management. It’s out of our control.
The good news is that top growth will be driven by new products or sales channels + higher profitability. Looking forward to next couple of years & seeing pipeline grow.
News 
Market Data 
Discover 
